HUTCHMED (NASDAQ:HCM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday.
Separately, HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Check Out Our Latest Stock Analysis on HUTCHMED
HUTCHMED Price Performance
Shares of NASDAQ:HCM traded down $0.82 during mid-day trading on Friday, reaching $16.90. 159,752 shares of the company's stock were exchanged, compared to its average volume of 99,837. The business's fifty day moving average price is $14.35 and its 200-day moving average price is $14.78. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $21.50.
Hedge Funds Weigh In On HUTCHMED
Hedge funds have recently bought and sold shares of the company. Barclays PLC raised its stake in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares during the last quarter. Summit Trail Advisors LLC raised its stake in HUTCHMED by 7.7% during the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock worth $212,000 after buying an additional 1,004 shares during the last quarter. OLD Mission Capital LLC bought a new position in HUTCHMED during the fourth quarter worth $230,000. Finally, Marshall Wace LLP bought a new position in HUTCHMED during the fourth quarter worth $261,000. Institutional investors own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
